Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 11/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.42 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927842 | 0.85 | HTR2C (0.54) | HTR6HTR2C | |
| SCHEMBL23927883 | 0.80 | HTR2C (0.51) | HTR2C | |
| SCHEMBL23927871 | 0.79 | PPARD (0.48) | LTB4RLTB4R2BCL2MCL1SRD5A2 | |
| SCHEMBL27605562 | 0.79 | APAF1 (0.47) | LTB4RLTB4R2BCL2MCL1ROCK1 | |
| SCHEMBL23927824 | 0.77 | KMT2A (0.44) | MCL1HTR2C | |
| Fumaric Acid SCHEMBL29435347 | 0.76 | HTR2C (0.50) | LTB4RLTB4R2BCL2MCL1HTR6 | |
| Fumaric Acid SCHEMBL23927910 | 0.76 | HTR2C (0.50) | LTB4RLTB4R2BCL2MCL1HTR6 | |
| SCHEMBL4323501 | 0.75 | HTR6 (0.52) | BCL2MCL1ROCK1HTR6HTR2C | |
| SCHEMBL20337878 | 0.74 | ALDH1A1 (0.49) | LTB4RLTB4R2BCL2MCL1ROCK1 | |
| SCHEMBL4328875 | 0.73 | HTR6 (0.52) | BCL2MCL1ROCK1HTR6SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | LTB4R 1932/4885LTB4R2 1648/4885BCL2 1487/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | LTB4R 1932/4885LTB4R2 1648/4885BCL2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.